Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | ADH1B | P00325 | 1/20 | 0.50 |
| ▸ | ADH1C | P00326 | 1/20 | 0.50 |
| ▸ | ADH1A | P07327 | 1/20 | 0.50 |
| ▸ | ADH7 | P40394 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ACP3 | P15309 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | CASR | P41180 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7922002 | 1.00 | SIGMAR1 (0.55) | SIGMAR1ADH1BADH1CADH1AADH7 | |
| SCHEMBL10695877 | 1.00 | SIGMAR1 (0.55) | SIGMAR1ADH1BADH1CADH1AADH7 | |
| SCHEMBL21193056 | 0.80 | SIGMAR1 (0.55) | SIGMAR1ADH1BADH1CADH1AADH7 | |
| SCHEMBL6601694 | 0.78 | SIGMAR1 (0.49) | SIGMAR1ADH1BADH1CADH1AADH7 | |
| SCHEMBL20012288 | 0.78 | SIGMAR1 (0.49) | SIGMAR1ADH1BADH1CADH1AADH7 | |
| SCHEMBL10696254 | 0.77 | SIGMAR1 (0.61) | SIGMAR1ADH1BADH1CADH1AADH7 | |
| SCHEMBL9063684 | 0.77 | SIGMAR1 (0.61) | SIGMAR1ADH1BADH1CADH1AADH7 | |
| SCHEMBL13675822 | 0.77 | SIGMAR1 (0.61) | SIGMAR1ADH1BADH1CADH1AADH7 | |
| SCHEMBL20012472 | 0.77 | SIGMAR1 (0.47) | SIGMAR1ADH1BADH1CADH1AADH7 | |
| SCHEMBL29255909 | 0.77 | SIGMAR1 (0.47) | SIGMAR1ADH1BADH1CADH1AADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103936759-B | (3aS, 6aR)-1,3-dibenzyl-tetrahydrochysene-4H-thieno-[3,4-d] imidazoles-2,4-(1H) simple and convenient process for preparing of-diketone | XINFA PHARMACEUTICAL CO., LTD. (CN) | 2016-01-13 | — | — | CN | disclosed |
| CN-103936759-A | Simple preparation method for (3aS,6aR)-1,3-dibenzyl-tetrahydro-4H-thieno[3,4-d]imidazole-2,4-(1H)-dione | XINFA PHARMACEUTICAL CO LTD | 2014-07-23 | — | — | CN | disclosed |
| US-8207170-B2 | Heterocyclic substituted piperazines with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2012-06-26 | — | — | US | disclosed |
| EP-1853587-B1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE OR PHENYL COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORP (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110065651-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065651-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES WITH CXCR3 ANTAGONIST ACTIVITY | CXCR3, CXCR1, CCR5 | SIGMAR1 1293/4885ADH1B 1933/4885ADH1C 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.